Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

Table 2 Calculation of dosing for FTD/TPI in mg according to BSA used in the TRITICC trial

Starting dose 25 mg/m²	BSA (m²)	Dose in mg 2 × daily	Tablets per dose		Total daily dose (mg)
Starting dose 25 mg/m²	BSA (m²)	Dose in mg 2 × daily	15 mg	20 mg	Total daily dose (mg)
	< 1.10	25!	2!	1!	50!
	1.10 – 1.29	30	2	0	60
	1.30 – 1.49	35	1	1	70
	1.50 – 1.69	40	0	2	80
	1.70 – 1.89	45	3	0	90
	1.90 – 2.09	50	2	1	100
	2.10 – 2.29	55	1	2	110
	> 2.30	60	0	3	120

(!) At a total daily dose of 50 mg, patients should take 1 × 20 mg tablet in the morning and 2 × 15 mg tablets in the evening

ISSN: 1471-2407